| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5174604
Max Phase: Preclinical
Molecular Formula: C20H22N2O5
Molecular Weight: 370.40
Associated Items:
Representations
Canonical SMILES: CN1CC[C@@H](c2c(O)cc(O)c3c2OC(c2ccncc2)CC3=O)[C@@H](O)C1
Standard InChI: InChI=1S/C20H22N2O5/c1-22-7-4-12(16(26)10-22)18-13(23)8-14(24)19-15(25)9-17(27-20(18)19)11-2-5-21-6-3-11/h2-3,5-6,8,12,16-17,23-24,26H,4,7,9-10H2,1H3/t12-,16+,17?/m1/s1
Standard InChI Key: GVAPNIRMICAXNV-KOEKDOOYSA-N
Associated Targets(Human)
Cyclin-dependent kinase 4/cyclin D1 2340 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 370.40 | Molecular Weight (Monoisotopic): 370.1529 | AlogP: 1.98 | #Rotatable Bonds: 2 |
| Polar Surface Area: 103.12 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 3 |
| #RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 8.24 | CX Basic pKa: 7.06 | CX LogP: 1.15 | CX LogD: 1.17 |
| Aromatic Rings: 2 | Heavy Atoms: 27 | QED Weighted: 0.74 | Np Likeness Score: 1.26 |
References
| 1. Shi Z, Tian L, Qiang T, Li J, Xing Y, Ren X, Liu C, Liang C.. (2022) From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy., 65 (9.0): [PMID:35485642] [10.1021/acs.jmedchem.1c02064] |
Source
Source(1):